recombinantbaculovirus(rHA0).Thisalternative avoids dependence on eggs and is very efficient because of the high levels of protein expression under the control of the baculovirus polyhedrin promoter. Monovalent and bivalent baculovirus-derived influenza vaccines have been evaluated in young adults and in community-dwelling adults older than 65 years. [3] [4] [5] [6] These studies found that the vaccines are well tolerated and immunogenic. Recently, doses of a trivalent vaccine ranging from 15 µg to 135 µg per component were shown to be well tolerated in elderly persons and to induce antibody responses at rates comparable with or superior to the licensed trivalent vaccine. 7 While a clear dose-response relationship has been shown for the H3 component in both healthy adults and in elderly persons, relatively little difference hasbeenobservedintheimmuneresponse to doses ranging from 15 µg to 135 µg of the H1 and B components. However, this analysis has been confounded by a poor correlation between the antigen content of the H1 and B components of rHA0 vaccines, as determined by measurement of total protein content, compared with the values determined by single radial immunodiffusion(SRID),thestandardmeasurement used for trivalent inactivated vaccine (TIV).
Therefore, the primary objective of the current study was to evaluate the relative immunogenicity of the H1 and B components of the vaccine when formulated at either 15 µg or 45 µg per component, as determined by SRID. In addition, we used the opportunity to follow up participants throughout the influenza season to obtain preliminary evidence of protective efficacy in a healthy adult population.
METHODS Vaccine
The vaccine used in this study consisted of purified HA proteins produced in insect cells using a baculovirus expression system, as previously described. 7 Because the HA produced in this system is not cleaved, the resulting product is referred to as rHA0. The vaccine was formulated as a trivalent prepa-ration containing the purified rHA0 of the A/New Caledonia/20/99(H1N1), A/Wyoming/3/03(H3N2), and B/Jiangsu/ 10/03 influenza viruses expressed from genes cloned by reverse transcriptase polymerase chain reaction from the same Centers for Disease Control and Prevention (CDC)-derived vaccine seed viruses used for the licensed TIV and formulated in phosphate-buffer saline containing 0.005% detergent without preservative. Sodium dodecyl sulfatepolyacrylamide gel electrophoresis of the purified monovalent materials indicated that hemagglutinin constitutes approximately 95% of the total protein.
The experimental vaccine was formulated at 2 different concentrations, as determined by SRID. The high-dose formulation contained 45 µg of each component, for a total dose of 135 µg of rHA0 per 0.5-mL dose based on the SRID values on the preblend bulk. After formulation, it was determined that this dose contained 35 µg rather than 45 µg of the H1 component. The low-dose formulation contained 45 µg of the H3 rHA0 and 15 µg each of the H1 and B rHA0, for a total dose of 75 µg of rHA0. Placebo consisted of normal saline for injection. Vaccine and placebo were supplied in coded, identical-appearing single-dose vials.
Clinical Study Design
The study was conducted as a randomized, double-blind, placebo-controlled study at 3 medical centers (University of Rochester, Rochester, NY; Cincinnati Children'sHospital,Cincinnati,Ohio;and University of Virginia, Charlottesville) during the 2004-2005 influenza season. Participants were healthy adults aged 18 to 49 years who did not belong to highpriority target groups for influenza vaccination as defined by the Advisory Committee on Immunization Practices and who had not received previous influenza vaccination for the 2004-2005 season. Women of childbearing potential had to have a negative urine pregnancy test result at the time of randomization and be willing to use an adequate form of contraception during the course of the study. Participants were recruited by newspaper and radio advertisements, posters, and word of mouth. Race/ethnicity data for all particiapnts were collected from selfreports. Participants were compensated for each visit (Ϸ$25).
After screening medical history and physical examination to determine eligibility, 10 mL of blood was collected from an arm vein for serologic studies, and participants were randomly assigned to receive a single dose of either rHA0 at 135 µg, rHA0 at 75 µg, or saline placebo using a permuted-block randomization scheme stratified by study site. Vaccine was administered as a single intramuscular injection in the upper deltoid.
Participants measured their oral temperature daily and maintained a diary card for 7 days after vaccination on which they recorded local and systemic reactions graded as mild (noticeable but not interfering with normal activities), moderate (some interference with normal activities), and severe (symptom prevented normal daily activities). Participants also returned on day 2 and day 7 after vaccination for review of the diary card, concomitant medications and medical history, and examination of the vaccination site. Participants returned approximately 28 days after vaccination for review of interim medical history. In addition, 10 mL of venous blood was obtained from an arm vein for assessment of antibody to influenza virus. A final study visit occurred at day 180, during which participants underwent a physical examination and interval medical history.
The study protocol was reviewed and approved by the investigational review boards at all 3 clinical sites, and written informed consent was obtained from all participants prior to study entry.
Surveillance for Influenza
Following the day 28 visit, participants started to complete a weekly diary to record influenza symptoms, and after influenza was recognized in the community, participants received weekly telephone callstoreviewthediaryandascertainpresence or absence of respiratory illness symptoms. Participants were instructed to return to the clinic for illness evaluations if they observed any acute respira-torytractsymptomsorfever.Duringthese illness visits, symptoms were reviewed, a brief physical examination was conducted, and nasopharyngeal swabs for virus culture were obtained.
Laboratory Assays
Serum samples were assessed for antibody to each of the 3 components of the vaccine by hemagglutination inhibition (HAI) using standard methods. Egg-grown influenza A/New Caledonia/ 20/99 and influenza A/Wyoming/ 03/03 were obtained from the CDC, Atlanta, Ga, while assays against the influenza B/Jiangsu/10/03 used antigen prepared in Madin-Darby canine kidney cells from a seed virus supplied by the CDC. Serum samples were treated with neuraminidase (receptordestroying enzyme, Denka Seiken, Tokyo, Japan) to remove nonspecific inhibitors of hemagglutination prior to testing and were tested in serial 2-fold dilutions at an initial dilution of 1:4. Serum samples with no reactivity at 1:4 were assigned a value of 1:2. Assays were performed using chick red blood cells (Colorado Serum Company, Denver) for influenza A/New Caledonia/ 20/99 and B/Jiangsu/10/03 viruses and turkey red blood cells (Viromed Laboratories, Minnetonka, Minn) for the influenza A/Wyoming/03/03 virus. Nasopharyngealswabsforvirusculture were stored at −70°C and shipped on dry icetoacentrallaboratory(CincinnatiChildren's Hospital Medical Center), where virus isolation was performed in primary rhesus monkey kidney cells (Diagnostic Hybrids Inc, Athens, Ohio). The presence of influenza A or B viruses in the culture was determined by immunofluorescence using type-specific monoclonal antibodies (Diagnostic Hybrids Inc). Influenza A isolates were further subtyped at Protein Sciences Corp by sequence analysis of the entire HA1 region after reverse transcriptase-polymerase chain reaction amplification of Madin-Darby canine kidney cell-grown virus.
Definition of End Points
The primary safety end points for this study were the rates and severity of solic-ited and unsolicited adverse events. The primaryimmunogenicityendpointswere the rates of 4-fold or greater increases in serum HAI antibody to each of the 3 vaccinestrainscomparingprevaccinationand 28-day postvaccination samples. The prespecified primary efficacy end point was culture-documentedinfluenzaillness,defined as development of a CDC-defined influenza-like illness associated with recovery of influenza virus from a nasopharyngeal swab. A CDC-defined influenzalike illness was defined as the presence of documentedfeverwithbodytemperature higher than 37.7°C (99.8°F) plus either sore throat or cough.
Statistical Analyses
Rates of safety end points were based on the most severe response and were evaluated by 2 test. Differences between the proportions of participants with at least a 4-fold increase in HAI antibody for each pairwise treatment group comparison were tested using a ² test.
The sample size for this study was chosenprimarilybasedontheimmunogenic-ity end point. Assuming that from 60% to80%oftheparticipantsinanactivetreat-mentgroupwouldhavea4-foldorgreater serum HAI antibody response to any specific strain, inclusion of 150 participants per group would have 80% power to detect an approximately 13% to 14% difference in response rates between study groups. Although not designed primarily as an efficacy trial, with a 5% attack rate intheplacebogroup,thestudyhadpower ranging from 14% to 53% to detect vaccine efficacy ranging from 40% to 80%. A PϽ.05 level was considered to be statistically significant. The analyses were conductedusingSASsoftware,version9.1 (SAS Institute Inc, Cary, NC).
RESULTS
A total of 460 participants were randomized, 458 were vaccinated, and 451 (98.5%) completed all study procedures. The disposition of the participants is shown in the FIGURE. Of the 460 enrolled participants, 153 were randomized to 75 µg of rHA0 vaccine, 153 were randomized to 135 µg of rHA0 vaccine, and 154 
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©2007 American Medical Association. All rights reserved. were randomized to placebo. There were 9 participants who did not complete the study, including 1 who withdrew consent, 5 who were lost to follow-up, 2 participants in the 75-µg rHA0 treatment group who were randomized but not vaccinated, and 1 who was incarcerated. The majority of participants were white (86%) and female (63%) (TABLE 1). The mean age was 31.7 years (range, 18-49 years). There were no differences with respect to age, sex, or race/ethnicity between the groups.
Assessment of Vaccine Safety
The rates and severities of local and systemic symptoms reported on the diary card are shown in TABLE 2. Injection of rHA0 vaccine was associated with local injection site pain that was significantly more frequent than after saline placebo and that was dose dependent (PϽ.001 for pain; P=.04 for tenderness). How-ever, 97% of all reports of pain after rHA0 vaccine were rated as mild. Systemic symptoms following vaccination also did not occur at significantly different rates in vaccine and placebo recipients (PϾ.07 for all comparisons). The most frequently reported systemic symptom following vaccination was headache. The majority (86%) of reports of headache were also rated as mild, and there was no difference in the frequency of headache between vaccine and placebo recipients (PϾ.07). There were no reported fevers (oral temperature Ͼ37.7°C [Ͼ99.8°F]) following vaccination. Two participants (1%) in the 135-µg vaccine group experienced serious adverse events that were considered to be unrelated to vaccine (1 seizure related to hypoglycemia and 1 newly diagnosed lobular carcinoma in situ). Two additional participants (1 in the 75-µg vaccine group and 1 in the 135-µg vaccine group) experienced severe adverse events (1 infected nevus and 1 knee injury) that were also considered to be unrelated to vaccine. No participants discontinued the study because of adverse events and no participants died.
Immunogenicity
Serum antibody responses to vaccination are summarized in TABLE 3. Overall, amongparticipantsvaccinatedwithrHA0 vaccine, the frequencies of HAI antibody responses (Ն4-fold increase comparing day 0 with day 28) to influenza A/New Caledonia, B/Jiangsu, and A/Wyoming were significantly greater (range, 51%-92%) than was observed for participantsvaccinatedwithplacebo(range,3%-11%; PϽ.001). Antibody responses were seen in most participants receiving either the 75-µg or the 135-µg dose of rHA0 vaccines.However,thefrequencyofresponses to both the A/New Caledonia/99 and B/Jiangsu/03 influenza viruses were significantly higher in the group receiving the135-µgdose(P=.003),consistentwith the higher doses of H1 and B components in the 135-µg vaccine. The frequency of HAIantibodyresponsetotheA/Wyoming/ 03 (H3N2) influenza virus was not different between the 75-µg and 135-µg doses,whichcontainedidenticalamounts oftheH3component.Similarly,therewere significant differences in the day 28 geo-metricmeantiterofHAIantibodybetween the 75-µg and 135-µg doses for both the H1 and B components but not the H3 component. 
Protection Against Influenza Illness
Participants in this study were followed throughout the subsequent influenza season with weekly telephone calls and instructed to return to the study clinics for anyacuterespiratoryillness,atwhichtime a nasopharyngeal swab for viral culture was obtained. A total of 116 such cultures were obtained, 43 in the placebo group, 39 in the 75-µg vaccine group, and 34 in the 135-µg vaccine group. The primary efficacy end point for this study was the development of culture-confirmed influenza illness meeting the influenza-like illness case definition of the CDC; ie, presence of fever higher than 37.7°C (99.8°F) and sore throat, cough, or both. There were a total of 13 positive cultures for influenza in the study population, of which 10 were influenza A (all of which were confirmed as influenza H3) and 3 were influenza B. Sequence analysis of these viruses further revealed that all of the 10 H3N2 isolates were A/California/7/2004-like. Of these 13 cases, 9 (69%) occurred in individuals meeting the CDC influenza illness case definition. The rates of culturepositive influenza illness, the prespecified primary efficacy end point, were 7 (4.6%) of 153 placebo recipients, 2 (1.4%) of 150 recipients of the 75-µg vaccine dose, and 0 of 151 recipients of the 135-µg vaccine dose. Among the 4 positive cultures in individuals who did not meet the CDC case definition, 1 occurred in a placebo recipient, 2 occurred in recipients of the 75-µg vaccine, and 1 occurred in a recipient of the 135-µg vaccine, so the rates of participants with a positive culture associated with any acute respiratory illness were 8/153 (5.2%), 4/150 (2.7%), and 1/151 (0.7%) in placebo, 75-µg vaccine, and 135-µg vaccine recipients, respectively.
COMMENT
We evaluated the safety, immunogenicity, and efficacy of a trivalent recombinant hemagglutinin (rHA0) vaccine. We have shown that the rHA0 vaccine is well tolerated in healthy adults and immunogenic at both doses evaluated, and we obtained preliminary evidence of protection against influenza infection and disease. The safety data generated in this study are consistent with the safety profile observed in previous studies of rHA0 vaccine. [3] [4] [5] [6] [7] [8] These vaccines have been well tolerated at all doses administered and are associated with low rates of local reactions. Because of widespread shortages of licensed TIV in the United States in 2004-2005, we were unable to perform a direct comparison of trivalent rHA0 vaccines and TIV. In other studies of TIV in healthy adult populations, pain at the injection site has been reported in 54% to 67% of recipients, [9] [10] [11] and systemic symptoms have been similar to placebo, suggesting that the trivalent rHA0 vaccine and TIV have a similar safety profile. This is consistent with previous direct comparisons of rHA0 and TIV suggesting similar rates of local reactions between the 2 vaccines. 3, 4, 7 Both doses of the recombinant hemagglutininvaccineevaluatedinducedserum HAI antibody responses to all 3 components (H1, H3, and B) in the majority of recipients. As expected, there were no differences in either the frequency of responses or the postvaccination geometric mean titer to influenza A/Wyoming (H3N2) between the 75-µg and 135-µg doses, since both doses contain the same 45 µg of the H3 component. Significant differences in both the frequency and the magnitudeoftheHAIresponseweredemonstrated for both the H1 and B components. Although the responses to the 75-µgdoseexceededtheEuropeanUnioncriteria for influenza vaccine licensure, 12 the 135-µg dose (45 µg of each component) wasmoreimmunogenicandmightbepredicted to provide greater or longer-lasting protection. Therefore, further develop-mentoftherHA0vaccineshoulduseaformulation of 45 µg per component, and future studies should directly compare the safety and immunogenicity of this dose with that of TIV. A major advantage of the rHA0approachisthatthesedosesarewell within the production capacity of the systemataneconomicallyandlogisticallyfeasible scale.
We also found that recipients of the rHA0 vaccine had reduced rates of culture-positive CDC-defined influenzalike illness compared with placebo recipients, although the study was small. When considering both vaccine groups combined, the cumulative incidence of culture positive CDC-defined influenzalike illness was reduced by 86%. For comparison, in a recently reported study conducted in the same influenza season as was our study, the efficacy of TIV in healthy adults against cultureconfirmed influenza meeting a similar case definition was 77% (95% confidence interval, 37%-92%) 11 The majority of cases in this study were due to influenza A, and all of the influenza A viruses isolated in this study that were further subtyped were of the H3N2 subtype,consistentwiththereportthat98.5% of all influenza A viruses typed in the United States during the 2004-2005 season were H3N2. 13 In addition, all of the influenza A(H3N2) viruses isolated from 
